CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant - Full Text View

CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

This study is ongoing, but not recruiting participants.

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00186680

Purpose

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Condition	Intervention	Phase
Breast Cancer	Procedure: high dose chemo then auto hematopoietic cell transplant	Phase I Phase II

Genetics Home Reference related topics:

breast cancer

MedlinePlus related topics:

Breast Cancer Cancer

Drug Information available for:

Cyclophosphamide Cisplatin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment

Official Title:	Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Further study details as provided by Stanford University:

Primary Outcome Measures:

Feasibility and safety

Secondary Outcome Measures:

efficiency of mobilization
tumor contamination

Study Start Date:

September 1996

Eligibility

Ages Eligible for Study:	19 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

stage IV breast cancer
primary breast cancer does not express CD34+
adequate organ function
no evidence of active infection

Exclusion Criteria:

chemotherapy within 4 weeks
CNS disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186680

Locations


United States, California
	Stanford University Cancer Center
	Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Investigators


Principal Investigator:	Ginna Laport, MD	Stanford University

More Information

Study ID Numbers:	BMT86
First Received:	September 14, 2005
Last Updated:	July 10, 2007
ClinicalTrials.gov Identifier:	NCT00186680
Health Authority:	United States: Institutional Review Board

Keywords provided by Stanford University:

Stage IV Breast Cancer

Study placed in the following topic categories:

Cisplatin

Skin Diseases

Breast Neoplasms

Cyclophosphamide

Breast Diseases

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on October 24, 2008